- Home
- EVM vs BMEA Comparison
EVM vs BMEA Comparison
Compare EVM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- BMEA
- Stock Information
- Founded
- EVM 2002
- BMEA 2017
- Country
- EVM United States
- BMEA United States
- Employees
- EVM N/A
- BMEA N/A
- Industry
- EVM Finance/Investors Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- EVM Finance
- BMEA Health Care
- Exchange
- EVM Nasdaq
- BMEA Nasdaq
- Market Cap
- EVM 233.7M
- BMEA 275.6M
- IPO Year
- EVM N/A
- BMEA 2021
- Fundamental
- Price
- EVM $9.45
- BMEA $6.53
- Analyst Decision
- EVM
- BMEA Buy
- Analyst Count
- EVM 0
- BMEA 13
- Target Price
- EVM N/A
- BMEA $37.25
- AVG Volume (30 Days)
- EVM 55.8K
- BMEA 817.8K
- Earning Date
- EVM 01-01-0001
- BMEA 10-29-2024
- Dividend Yield
- EVM 4.01%
- BMEA N/A
- EPS Growth
- EVM N/A
- BMEA N/A
- EPS
- EVM 0.20
- BMEA N/A
- Revenue
- EVM N/A
- BMEA N/A
- Revenue This Year
- EVM N/A
- BMEA N/A
- Revenue Next Year
- EVM N/A
- BMEA N/A
- P/E Ratio
- EVM $47.61
- BMEA N/A
- Revenue Growth
- EVM N/A
- BMEA N/A
- 52 Week Low
- EVM $7.67
- BMEA $3.61
- 52 Week High
- EVM $9.59
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- EVM 56.53
- BMEA 23.64
- Support Level
- EVM $9.25
- BMEA $8.60
- Resistance Level
- EVM $9.36
- BMEA $9.34
- Average True Range (ATR)
- EVM 0.08
- BMEA 0.79
- MACD
- EVM 0.03
- BMEA -0.40
- Stochastic Oscillator
- EVM 94.03
- BMEA 0.82
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income and alternative strategies to institutional investors, both in the United States and internationally.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.